Evofem Biosciences, Inc. (EVFM) financial statements (2020 and earlier)

Company profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments16131138
Cash and cash equivalents16131138
Restricted cash and investments00   
Other undisclosed current assets111112
Total current assets:26241340
Noncurrent Assets
Property, plant and equipment01 00
Restricted cash and investments  0  
Other noncurrent assets11   
Other undisclosed noncurrent assets0  00
Total noncurrent assets:22000
TOTAL ASSETS:28441340
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1223115
Accounts payable69114
Accrued liabilities312101
Employee-related liabilities43   
Debt 4  3
Other undisclosed current liabilities0  01
Total current liabilities:1327119
Noncurrent Liabilities
Long-term debt and lease obligation    7
Long-term debt, excluding current maturities    7
Liabilities, other than long-term debt 0   
Deferred revenue and credits0   
Total noncurrent liabilities: 0  7
Total liabilities:13271116
Stockholders' equity
Stockholders' equity attributable to parent16(23)31224
Common stock00000
Additional paid in capital529410139138137
Accumulated deficit(513)(433)(136)(126)(113)
Total stockholders' equity:16(23)31224
TOTAL LIABILITIES AND EQUITY:28441340

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(53)(78)(10)(12)(42)
Operating loss:(53)(78)(10)(12)(42)
Nonoperating income (expense)(27)(48)000
Investment income, nonoperating00000
Interest and debt expense   (1)(1)
Loss from continuing operations before income taxes:(80)(126)(10)(13)(43)
Income tax expense(0)(0)   
Net loss attributable to parent:(80)(126)(10)(13)(43)
Preferred stock dividends and other adjustments (0)   
Net loss available to common stockholders, diluted:(80)(126)(10)(13)(43)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(80)(126)(10)(13)(43)
Comprehensive loss, net of tax, attributable to parent:(80)(126)(10)(13)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: